Posted inClinical Updates Hematology-Oncology news
Combining Midostaurin with Low-Dose Cytarabine and Venetoclax in Older Adults with Newly Diagnosed AML: Evidence and Implications from the INTERVENE Phase 2 Trial
The INTERVENE trial reveals that adding midostaurin to low-dose cytarabine and venetoclax is tolerable and improves FLT3-ITD clearance and survival in older AML patients with FLT3-ITD, addressing resistance in this high-risk subgroup.
